The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Li-Fraumeni syndrome – a molecular and clinical review
Open accessAbstract
In 1969 Li and Fraumeni identified, from a systematic study of 648 children with rhabdomyosarcomas, five families in which a sibling or a cousin was affected by sarcoma (Li and Fraumeni, 1969a, b). A prospective study of four of the original families indicated that there was a significantly increased risk of cancer within these families, particularly premenopausal breast cancer, as well as a significant excess of second malignancies (Li and Fraumeni, 1982). The term 'Li-Fraumeni syndrome' was used initially by Pearson et al (1982) and is now the most common term for this dominant inherited cancer syndrome. Studies from our own group on a population-based series of children with soft-tissue sarcoma (Birch et al, 1984; 1990) and a USA hospital-based series of survivors of childhood soft-tissue sarcomas from Strong's group in the USA (Strong et al, 1987) confirmed that the familial clustering was due to inherited predisposition and not to environmental factors. Twenty-four families, defined using strict criteria, were subsequently studied by the Li and Fraumeni groups (Li et al, 1988). Such families are now regarded as having 'classic' Li-Fraumeni syndrome (LFS), namely a proband aged under 45 years with a sarcoma having a first-degree relative aged under 45 years with any cancer and an additional firstor second-degree relative aged under 45 years in the same lineage with any cancer or a sarcoma at any age (Li et al, 1988). This study by Li et al (1988) indicated that the spectrum of tumours within the syndrome included acute leukaemia, premenopausal breast carcinoma, brain and adrenocortical tumours as well as bone and soft-tissue sarcomas. Other studies have indicated that a number of other cancers may occur at an increased frequency in these families, notably melanoma, germ cell tumours, Wilms' tumours, gastric and pancreatic carcinomas and lung cancer (Hartley et al, 1987; 1989; Strong et al, 1987; Varley et al, 1995; 1997a). While the definition of classic LFS has become generally accepted, a number of groups have relaxed the description to include incomplete Li-Fraumeni syndrome (a proband with an affected first-degree relative; Brugieres et al, 1993) and LiFraumeni-like syndrome (LFL). Two groups have defined LFL families independently but using different criteria. Eeles (1995) defined LFL as a clustering of two different tumours (both characteristic of LFS) in individuals who are firstor second-degree relatives of any age. Our own group has defined LFL by more stringent criteria: a proband with any childhood tumour or sarcoma, brain tumour or adrenocortical tumour under 45 years plus a firstor second-degree relative with a typical LFS tumour at
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Cited by
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
Self-citationRubbi, C. P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg579 · Cited by 811
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Prevalence and natural history of adrenal incidentalomas
Barzon, L., Sonino, N., Fallo, F., Palu, G., & Boscaro, M. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490273 · Cited by 642
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 557
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
A continuum model for tumour suppression
Berger, A. H., Knudson, A. G., & Pandolfi, P. P. (2011) · Nature · doi:10.1038/nature10275 · Cited by 501
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
Self-citationConstitutional Mutations of the hSNF5/INI1 Gene Predispose to a Variety of Cancers
Sévenet, N., Sheridan, E., Amram, D., Schneider, P., Handgretinger, R., & Delattre, O. (1999) · The American Journal of Human Genetics · doi:10.1086/302639 · Cited by 450
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
Self-citation(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1167 · Cited by 372
Molecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Sensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341
RNA polymerases I and III, growth control and cancer
White, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1551 · Cited by 333
Daly, M. B., Pal, T., Maxwell, K. N., Churpek, J., Kohlmann, W., AlHilli, Z., Arun, B., Buys, S. S., Cheng, H., Domchek, S. M., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0051 · Cited by 315
Cell cycle control, checkpoint mechanisms, and genotoxic stress.
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s15 · Cited by 257
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Raymond, V. M., Else, T., Everett, J. N., Long, J. M., Gruber, S. B., & Hammer, G. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2198 · Cited by 105
Hendrickson, P. G., Luo, Y., Kohlmann, W., Schiffman, J., Maese, L., Bishop, A. J., Lloyd, S., Kokeny, K. E., Hitchcock, Y. J., Poppe, M. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3427 · Cited by 64
Unusual double primary neoplasia: adrenocortical and ureteral carcinomas in werner syndrome
Takazawa, R., Ajima, J., Yamauchi, A., & Goto, M. (2004) · Urologia Internationalis · doi:10.1159/000075974 · Cited by 11
Metadata
- Authors
- Varley, J., Evans, D., & Birch, J.
- Venue
- British Journal of Cancer
- Published
- 1997-07
- Volume
- 76
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2003090246
- Cited by
- 358
- References
- 111
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.